MARKET

MDCX

MDCX

Medicus Pharma Ltd
NASDAQ
0.3632
+0.0321
+9.70%
Opening 12:38 08/13 EDT
OPEN
0.3310
PREV CLOSE
0.3311
HIGH
0.3680
LOW
0.3250
VOLUME
858.92K
TURNOVER
--
52 WEEK HIGH
3.050
52 WEEK LOW
0.2500
MARKET CAP
22.95M
P/E (TTM)
-0.1359
1D
5D
1M
3M
1Y
5Y
1D
Medicus Pharma GAAP EPS of -$0.21
Seeking Alpha · 6h ago
Medicus Pharma Advances SkinJect and Teverelix Amid Financing Gains and Going-Concern Risk
TipRanks · 22h ago
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Barchart · 1d ago
Weekly Report: what happened at MDCX last week (0803-0807)?
Weekly Report · 3d ago
Weekly Report: what happened at MDCX last week (0727-0731)?
Weekly Report · 08/03 09:53
Medicus Pharma Teverelix granted investigational new drug authorization in UAE
TipRanks · 07/31 11:37
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Barchart · 07/31 06:30
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medicus Pharma Ltd (MDCX) and Altimmune (ALT)
TipRanks · 07/28 16:40
More
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Webull offers Medicus Pharma Ltd stock information, including NASDAQ: MDCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDCX stock methods without spending real money on the virtual paper trading platform.